Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07827079 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBC

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
To assess the efficacy and safety of tislelizumab combined with TAC as neoadjuvant therapy for triple-negative breast cancer, and to preliminarily investigate its underlying molecular mechanisms.
Trial Details
NCT Number NCT07827079
Lead Sponsor Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Conditions
(from sponsor)		 Breast Cancer (Triple Negative Breast Cancer (TNBC)), Chemeotherapy
Related terms Breast Neoplasms, Triple Negative Breast Neoplasms
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov